Wir sind mit live! Mehr erfahren

Kyntra Bio

KYNB

Börsenwert 19,6 Mio. $

4,85 USD

-0,51

9,51 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-9,51 %

5 Tage

-21,14 %

1 Monat

-36,27 %

3 Monate

-34,37 %

6 Monate

-32,55 %

Seit Jahresbeginn

-47,05 %

1 Jahr

-55,01 %

5 Jahre

-98,19 %

10 Jahre

-98,91 %

Profil: Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Mitarbeiter: 34

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 14,3 %

Neutral 71,4 %

Negativ 14,3 %

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The Company also announced that Maykin Ho, Ph.D. has stepped down from the Board of Directors effective September 30, 2026 after nearly eight years of service.

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.

Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment.

Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $4.68 per share versus the Zacks Consensus Estimate of a loss of $3.18. This compares to a loss of $3.38 per share a year ago.

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Zacks Investment Research

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026 in Stockholm, Sweden.

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estimate of a loss of $3.36. This compares to a loss of $4 per share a year ago.

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt